Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | B. Elenbaas, L. Singh,, A. Boccia,, P. Cullen, et al. | ||||||||||||
Title | 105 BIIB024, a potent pan-Raf kinase inhibitor for melanoma and solid tumors | ||||||||||||
|
|||||||||||||
URL | http://www.ejcancersupplements.com/article/S1359-6349%2810%2971810-3/abstract | ||||||||||||
Abstract Text | EJC Supplements , Volume 8 , Issue 7 , 40 - 41 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF mutant | Advanced Solid Tumor | predicted - sensitive | Tovorafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Ojemda (tovorafenib) inhibited downstream signaling and proliferation of several BRAF mutant solid tumor cell lines in culture (EJC Supp, Nov 2010, Vol 8(7), p40-41). | detail... |